These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
299 related items for PubMed ID: 21720253
21. Tamoxifen inhibits cell proliferation via mitogen-activated protein kinase cascades in human ovarian cancer cell lines in a manner not dependent on the expression of estrogen receptor or the sensitivity to cisplatin. Mabuchi S, Ohmichi M, Kimura A, Ikebuchi Y, Hisamoto K, Arimoto-Ishida E, Nishio Y, Takahashi K, Tasaka K, Murata Y. Endocrinology; 2004 Mar; 145(3):1302-13. PubMed ID: 14645110 [Abstract] [Full Text] [Related]
22. Nongenomic effect of estrogen on the MAPK signaling pathway and calcium influx in endometrial carcinoma cells. Zhang L, Li X, Zhao L, Zhang L, Zhang G, Wang J, Wei L. J Cell Biochem; 2009 Mar 01; 106(4):553-62. PubMed ID: 19160418 [Abstract] [Full Text] [Related]
27. The effect of estrogen on the proliferation of endometrial cancer cells is mediated by ERRγ through AKT and ERK1/2. Sun Y, Wang C, Yang H, Ma X. Eur J Cancer Prev; 2014 Sep 01; 23(5):418-24. PubMed ID: 25068805 [Abstract] [Full Text] [Related]
29. Delayed and persistent ERK1/2 activation is required for 4-hydroxytamoxifen-induced cell death. Zhou JH, Yu DV, Cheng J, Shapiro DJ. Steroids; 2007 Oct 01; 72(11-12):765-77. PubMed ID: 17714751 [Abstract] [Full Text] [Related]
30. Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells. Gilad LA, Bresler T, Gnainsky J, Smirnoff P, Schwartz B. J Endocrinol; 2005 Jun 01; 185(3):577-92. PubMed ID: 15930183 [Abstract] [Full Text] [Related]
31. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. Atanaskova N, Keshamouni VG, Krueger JS, Schwartz JA, Miller F, Reddy KB. Oncogene; 2002 Jun 06; 21(25):4000-8. PubMed ID: 12037682 [Abstract] [Full Text] [Related]
32. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Britton DJ, Hutcheson IR, Knowlden JM, Barrow D, Giles M, McClelland RA, Gee JM, Nicholson RI. Breast Cancer Res Treat; 2006 Mar 06; 96(2):131-46. PubMed ID: 16261397 [Abstract] [Full Text] [Related]
34. Role of PKC-ERK signaling in tamoxifen-induced apoptosis and tamoxifen resistance in human breast cancer cells. Li Z, Wang N, Fang J, Huang J, Tian F, Li C, Xie F. Oncol Rep; 2012 Jun 06; 27(6):1879-86. PubMed ID: 22427054 [Abstract] [Full Text] [Related]
35. Expression and activation of P38 MAP kinase in invasive ductal breast cancers: correlation with expression of the estrogen receptor, HER2 and downstream signaling phosphorylated proteins. Merlin JL, Harlé A, Lion M, Ramacci C, Leroux A. Oncol Rep; 2013 Oct 06; 30(4):1943-8. PubMed ID: 23900300 [Abstract] [Full Text] [Related]
38. Estrogens and ICI182,780 (Faslodex) modulate mitosis and cell death in immature cerebellar neurons via rapid activation of p44/p42 mitogen-activated protein kinase. Wong JK, Le HH, Zsarnovszky A, Belcher SM. J Neurosci; 2003 Jun 15; 23(12):4984-95. PubMed ID: 12832521 [Abstract] [Full Text] [Related]
39. Estrogen receptor protein interaction with phosphatidylinositol 3-kinase leads to activation of phosphorylated Akt and extracellular signal-regulated kinase 1/2 in the same population of cortical neurons: a unified mechanism of estrogen action. Mannella P, Brinton RD. J Neurosci; 2006 Sep 13; 26(37):9439-47. PubMed ID: 16971528 [Abstract] [Full Text] [Related]
40. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Hutcheson IR, Knowlden JM, Madden TA, Barrow D, Gee JM, Wakeling AE, Nicholson RI. Breast Cancer Res Treat; 2003 Sep 13; 81(1):81-93. PubMed ID: 14531500 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]